Pharmacology of Cardiac Glycosides and Inotropes

Introduction/Overview

The pharmacological modulation of cardiac contractility represents a cornerstone in the management of heart failure and certain arrhythmias. Agents that enhance the force of myocardial contraction, known as positive inotropes, have been utilized for centuries, with cardiac glycosides holding a particularly storied place in medical history. Despite the evolution of heart failure management towards neurohormonal blockade, these agents retain clinical relevance in specific patient populations. This chapter provides a systematic examination of the pharmacology of cardiac glycosides and other positive inotropic drugs, detailing their mechanisms, therapeutic applications, and significant limitations.

The clinical importance of these drugs is underscored by their narrow therapeutic index and the potential for severe toxicity. A precise understanding of their pharmacokinetics, pharmacodynamics, and interaction profiles is essential for safe and effective prescribing. Mastery of this topic enables clinicians to leverage the benefits of inotropic support while mitigating the considerable risks associated with these potent compounds.

Learning Objectives

• Describe the molecular and cellular mechanisms of action for cardiac glycosides and other major classes of positive inotropic agents.
• Compare and contrast the pharmacokinetic profiles of digoxin, dobutamine, and milrinone, including implications for dosing in special populations.
• Identify the approved clinical indications and evidence-based uses for cardiac glycosides and intravenous inotropes in contemporary practice.
• Recognize the signs, symptoms, and management strategies for acute and chronic toxicity associated with cardiac glycosides.
• Analyze major drug-drug interactions and contraindications for inotropic agents, with particular attention to conditions that predispose to digoxin toxicity.

Classification

Positive inotropic agents are classified based on their primary mechanism of action. This classification is clinically useful as it predicts hemodynamic effects, potential adverse reactions, and appropriate clinical scenarios for use.

Cardiac Glycosides (Digitalis Compounds)

This class comprises naturally occurring compounds and their semi-synthetic derivatives. They are characterized by a steroid nucleus (aglycone or genin) linked to one or more sugar molecules. The aglycone is essential for pharmacological activity, while the sugars influence pharmacokinetic properties like potency and duration of action.

• Digitalis purpurea glycosides: Digoxin, digitoxin.
• Digitalis lanata glycosides: Digoxin (primarily), lanatoside C.
• Strophanthus glycosides: Ouabain (g-strophanthin).

Digoxin is the prototypical and most widely used agent in this class in modern practice.

Beta-Adrenergic Receptor Agonists

These synthetic catecholamines exert inotropic effects primarily through stimulation of cardiac β₁-adrenergic receptors.

• Dobutamine: A relatively selective β₁-agonist.
• Dopamine: Dose-dependent activity on dopamine, β₁, and α₁ receptors.
• Epinephrine and Norepinephrine: Used in specific critical care settings for inotropic support, though their effects are mixed (inotropic, chronotropic, and vasopressor).

Phosphodiesterase III Inhibitors

These agents inhibit the enzyme phosphodiesterase type III (PDE-III), which is predominant in cardiac and vascular smooth muscle. This class is often termed “inodilators” due to combined inotropic and vasodilatory effects.

• Milrinone: A bipyridine derivative, most commonly used.
• Amrinone (Inamrinone): An older agent with greater potential for thrombocytopenia.

Calcium Sensitizers

This class enhances myocardial contractility by increasing the sensitivity of the cardiac contractile apparatus to intracellular calcium, without increasing calcium influx. Levosimendan is the primary example, though its availability varies globally. It also possesses PDE-III inhibitory and vasodilatory properties.

Mechanism of Action

The mechanisms by which these drugs increase cardiac contractility are distinct, leading to different hemodynamic and electrophysiological profiles.

Molecular and Cellular Mechanism of Cardiac Glycosides

The primary molecular target of cardiac glycosides is the sodium-potassium adenosine triphosphatase (Na⁺/K⁺-ATPase) pump on the sarcolemma of cardiomyocytes. This pump normally exports three sodium ions (Na⁺) and imports two potassium ions (K⁺) per cycle, utilizing ATP. By inhibiting this pump, cardiac glycosides produce a sequence of ionic shifts that culminate in enhanced contractility.

1. Na⁺/K⁺-ATPase Inhibition: Digoxin binds to a specific site on the extracellular α-subunit of the pump, reversibly inhibiting its activity.
2. Increase in Intracellular Sodium: Pump inhibition reduces the extrusion of Na⁺, leading to a modest accumulation of intracellular Na⁺.
3. Reduction of Sodium-Calcium Exchanger (NCX) Activity: The NCX normally uses the inward Na⁺ gradient to extrude one calcium ion (Ca²⁺) for the import of three Na⁺. The elevated intracellular Na⁺ reduces the gradient driving this exchange, thereby decreasing Ca²⁺ extrusion.
4. Increase in Intracellular Calcium: The net result is an increase in cytosolic Ca²⁺ during diastole. This Ca²⁺ is sequestered in the sarcoplasmic reticulum (SR).
5. Enhanced Calcium Transient: During the subsequent action potential, the SR releases a greater quantity of Ca²⁺, leading to a more robust interaction between actin and myosin filaments and thus increased force of contraction (positive inotropy).

This mechanism is often described as “indirect” as it does not involve direct stimulation of adrenergic receptors or cyclic nucleotide pathways. The inotropic effect occurs without a proportional increase in myocardial oxygen consumption, a distinction from catecholamines, because the enhanced contractility allows the heart to operate at a smaller, more efficient size (reduced ventricular wall tension via the Law of Laplace).

Electrophysiological Effects

Cardiac glycosides have complex electrophysiological actions that are dose-dependent and differ in atrial, ventricular, and specialized conduction tissue.

• Vagomimetic Effects: At low to therapeutic concentrations, digoxin increases parasympathetic (vagal) tone to the heart. This is mediated through sensitization of baroreceptors and direct central actions. The primary results are decreased sinoatrial (SA) node automaticity (slower heart rate) and prolonged refractory period of the atrioventricular (AV) node (slowed conduction).
• Direct Effects on Conduction Tissue: At higher concentrations, direct inhibition of Na⁺/K⁺-ATPase leads to increased intracellular Ca²⁺, which can promote delayed afterdepolarizations (DADs). This increased automaticity, particularly in Purkinje fibers and ventricular myocardium, can trigger serious arrhythmias.
• Electrocardiographic Manifestations: Therapeutic doses may cause PR interval prolongation, ST segment depression with a characteristic “scooping” morphology (digitalis effect), and shortening of the QT interval. Toxic doses can cause almost any arrhythmia, commonly including AV block, atrial tachycardia with block, premature ventricular contractions, bigeminy, and ventricular tachycardia.

Mechanism of Beta-Adrenergic Agonists

Dobutamine, the prototypical intravenous β-agonist for inotropy, acts primarily on cardiac β₁-adrenergic receptors. Receptor activation stimulates the membrane-bound G_s protein, which activates adenylyl cyclase. This enzyme converts ATP to cyclic adenosine monophosphate (cAMP). Elevated intracellular cAMP activates protein kinase A (PKA), which phosphorylates multiple targets:

• L-type Calcium Channels: Phosphorylation increases channel opening probability during the action potential plateau, enhancing Ca²⁺ influx.
• Phospholamban: Phosphorylation relieves its inhibition of the SR Ca²⁺-ATPase (SERCA), accelerating SR Ca²⁺ uptake and increasing SR Ca²⁺ stores available for release.
• Troponin I: Phosphorylation decreases myofilament sensitivity to Ca²⁺, contributing to enhanced relaxation (lusitropy).

The net effect is a rapid and significant increase in contractility. However, this is often accompanied by increased heart rate (chronotropy) and myocardial oxygen demand. Tolerance (tachyphylaxis) can develop with prolonged infusion due to β-receptor downregulation.

Mechanism of Phosphodiesterase III Inhibitors

Milrinone inhibits PDE-III, the enzyme responsible for degrading cAMP in cardiac and vascular smooth muscle cells. By preventing cAMP breakdown, milrinone increases intracellular cAMP levels independently of β-receptor stimulation. The subsequent activation of PKA produces effects similar to β-agonists in the heart (positive inotropy and lusitropy). In vascular smooth muscle, increased cAMP leads to PKA-mediated phosphorylation and inactivation of myosin light chain kinase, promoting vasodilation (arterial and venous). This combined inotropic and vasodilatory (inodilator) effect reduces both preload and afterload, which is particularly beneficial in heart failure with elevated systemic vascular resistance.

Mechanism of Calcium Sensitizers

Levosimendan enhances cardiac contractility by binding to troponin C in a calcium-dependent manner. This binding stabilizes the calcium-induced conformational change of troponin C, prolonging the interaction between actin and myosin without increasing intracellular calcium transients. This mechanism may offer an energetic advantage. Levosimendan also acts as a vasodilator by opening ATP-sensitive potassium (K_ATP) channels in vascular smooth muscle and has weak PDE-III inhibitory activity.

Pharmacokinetics

The pharmacokinetic profiles of these agents vary dramatically, influencing their route of administration, onset/duration of action, and suitability for acute versus chronic therapy.

Cardiac Glycosides: Digoxin

Absorption: Oral bioavailability of digoxin tablets is approximately 60-80%. It is a substrate for the efflux transporter P-glycoprotein (P-gp) in the gut, which influences its absorption. The elixir formulation has higher bioavailability (≈80-90%). Absorption can be slowed but not reduced by meals with a high fiber content.

Distribution: Digoxin has a large volume of distribution (V_d ≈ 5-8 L/kg), indicating extensive tissue binding. It distributes slowly into a “deep” peripheral compartment, primarily skeletal muscle. Equilibrium between plasma and tissue concentrations is not instantaneous, which is a critical concept when interpreting serum levels. Therapeutic serum concentrations are typically 0.5-0.9 ng/mL for heart failure; levels of 1.2 ng/mL or higher are associated with increased toxicity risk.

Metabolism: Only 10-20% of digoxin is hepatically metabolized. The majority is excreted unchanged by the kidneys. It is not a significant substrate for cytochrome P450 enzymes.

Excretion: Renal excretion of unchanged drug is the principal elimination pathway. It is filtered at the glomerulus and also actively secreted via P-gp in the renal tubules. Its elimination half-life (t_1/2) is normally 36-48 hours in patients with normal renal function. This t_1/2 is prolonged in renal impairment, as described by the relationship: t_1/2 ≈ (0.693 × V_d) ÷ CL_cr, where CL_cr is creatinine clearance. Dosing must be adjusted based on estimated renal function.

Intravenous Inotropes: Dobutamine and Milrinone

Dobutamine: Administered only by continuous intravenous infusion due to extensive first-pass metabolism. Onset of action is within 1-2 minutes. It is rapidly metabolized in the liver and other tissues by catechol-O-methyltransferase (COMT) and conjugation. Its plasma half-life is approximately 2 minutes, necessitating continuous infusion. Effects dissipate within 5-10 minutes of stopping the infusion.

Milrinone: Also administered intravenously, with an onset of action within 5-15 minutes. It is primarily eliminated renally (≈85% unchanged in urine), with a small fraction undergoing glucuronidation. Its half-life is approximately 2-3 hours in patients with normal renal function, but this can extend dramatically to over 20 hours in severe renal failure, requiring significant dose reduction and careful monitoring.

Therapeutic Uses/Clinical Applications

The use of positive inotropes is guided by the underlying pathophysiology, acuity of illness, and the specific hemodynamic goals of therapy.

Cardiac Glycosides (Digoxin)

• Chronic Heart Failure with Reduced Ejection Fraction (HFrEF): Digoxin is used as an adjunctive therapy to reduce hospitalizations for heart failure exacerbation. It does not confer a mortality benefit and is not a first-line agent. Its use is typically considered in patients who remain symptomatic despite guideline-directed medical therapy (GDMT) with ACE inhibitors/ARBs/ARNIs, beta-blockers, and MRAs. Its benefits are attributed to inotropy and, importantly, its vagomimetic effects which counteract excessive sympathetic tone.
• Rate Control in Atrial Fibrillation and Flutter: Digoxin is effective for controlling ventricular rate at rest, particularly in patients with heart failure or sedentary lifestyles. It is less effective for controlling rate during exercise (lack of sympathetic antagonism). It is often used in combination with a beta-blocker or non-dihydropyridine calcium channel blocker. Its AV nodal blocking action is primarily via enhanced vagal tone.

Intravenous Inotropes

These are reserved for acute, inpatient settings.

• Acute Decompensated Heart Failure (ADHF) with Hypoperfusion (Cardiogenic Shock): Dobutamine or milrinone may be used to augment cardiac output and improve end-organ perfusion. The choice between agents depends on the patient’s blood pressure and systemic vascular resistance (SVR). Dobutamine may be preferred when a mild increase in heart rate is acceptable and SVR is not severely elevated. Milrinone, with its vasodilatory properties, is often chosen in patients with elevated SVR and adequate blood pressure, but it can cause hypotension.
• Bridge Therapy: Short-term use as a “bridge” to more definitive therapy, such as cardiac transplantation or placement of a durable mechanical circulatory support device.
• Dobutamine Stress Echocardiography: Dobutamine infusion is used pharmacologically to simulate the stress of exercise on the heart, aiding in the diagnosis of coronary artery disease.
• Inotropic Support in Advanced Heart Failure: Intermittent or continuous outpatient infusion may be considered in select patients with end-stage heart failure who are not candidates for advanced therapies, though this is palliative and associated with significant risks.

Adverse Effects

The adverse effect profiles are extensive, particularly for cardiac glycosides, due to their narrow therapeutic index.

Cardiac Glycoside Toxicity

Toxicity can be chronic (due to accumulation) or acute (due to overdose). Predisposing factors include hypokalemia, hypomagnesemia, hypercalcemia, renal impairment, hypothyroidism, advanced age, and concomitant use of interacting drugs (e.g., amiodarone, verapamil).

• Gastrointestinal: Anorexia, nausea, vomiting, abdominal pain, and diarrhea are often early non-cardiac manifestations.
• Neurological/Central: Fatigue, malaise, headache, dizziness, confusion, delirium, and visual disturbances (chromatopsia – yellow/green halos around lights, blurred vision).
• Cardiac Arrhythmias: This is the most serious manifestation. Toxicity can cause almost any arrhythmia. Classic dysrhythmias include:
  • Bradyarrhythmias: Sinus bradycardia, sinoatrial arrest, various degrees of AV block.
  • Tachyarrhythmias: Atrial tachycardia with block, accelerated junctional rhythm, ventricular bigeminy/trigeminy, bidirectional ventricular tachycardia (highly specific for digoxin toxicity), and ventricular fibrillation.

Digoxin-specific antibody fragments (Digibind^®, DigiFab^®) are the definitive treatment for life-threatening toxicity. They bind free digoxin, forming complexes that are excreted renally.

Adverse Effects of Intravenous Inotropes

Dobutamine: Tachycardia, palpitations, hypertension or hypotension, ventricular ectopy, angina (due to increased myocardial oxygen demand), and anxiety. Tolerance develops with prolonged use.

Milrinone: Hypotension (from vasodilation), ventricular arrhythmias, headache, and thrombocytopenia (more common with amrinone).

Black Box Warnings: Both dobutamine and milrinone carry warnings regarding their use in patients with severe obstructive aortic or pulmonic valvular disease, as the inotropic effect may increase the pressure gradient, potentially worsening the condition. More importantly, long-term oral therapy with PDE-III inhibitors (e.g., milrinone) has been associated with increased mortality in chronic heart failure patients, reinforcing that their use should be restricted to short-term intravenous support.

Drug Interactions

Drug interactions are a major clinical concern, particularly for digoxin, and can precipitate toxicity or therapeutic failure.

Major Interactions with Digoxin

• Drugs that Reduce Renal Clearance or Displace Tissue Binding:
  • Amiodarone, Verapamil, Diltiazem, Quinidine: These drugs inhibit renal P-gp, reducing digoxin tubular secretion and significantly increasing serum digoxin concentrations (often by 50-100%). Dose reduction of digoxin by 30-50% is typically required when initiating these agents.
  • Cyclosporine, Itraconazole: Also potent P-gp inhibitors.
• Drugs that Cause Electrolyte Disturbances:
  • Diuretics (especially loop and thiazides): Can cause hypokalemia and hypomagnesemia, which potentiate digoxin toxicity by enhancing its binding to Na⁺/K⁺-ATPase and promoting arrhythmogenesis.
  • Amphotericin B, Corticosteroids: Can also cause hypokalemia.
• Drugs that Affect Absorption:
  • Cholestyramine, Colestipol, Kaolin-pectin: Bind digoxin in the gut, reducing absorption. Dosing should be separated by several hours.
  • Antacids, Proton Pump Inhibitors: May alter gastric pH and potentially reduce absorption, though this is less clinically significant.
• Sympathomimetics: Drugs like epinephrine can increase automaticity and may exacerbate the arrhythmogenic potential of digoxin.

Contraindications

• Absolute: Ventricular fibrillation, known hypersensitivity, and digoxin toxicity.
• Relative (Require Extreme Caution):
  • Hypertrophic obstructive cardiomyopathy (HOCM) – inotropy may worsen outflow tract obstruction.
  • Second- or third-degree AV block (unless a pacemaker is in place).
  • Wolff-Parkinson-White (WPW) syndrome with atrial fibrillation – digoxin can accelerate conduction down the accessory pathway, potentially leading to ventricular fibrillation.
  • Renal failure (requires dose adjustment and close monitoring).

Special Considerations

Pregnancy and Lactation

Digoxin: It is classified as Pregnancy Category C. It crosses the placenta, and fetal serum concentrations are similar to maternal levels. It can be used for maternal heart failure or fetal supraventricular tachycardia. It is excreted in breast milk, but infant exposure is considered low and usually not clinically significant; monitoring of the infant is recommended.

Intravenous Inotropes: Dobutamine is Category B; milrinone is Category C. Their use in pregnancy is limited to critical maternal situations where the potential benefit justifies the potential fetal risk.

Pediatric Considerations

Digoxin is used in pediatric patients, particularly for heart failure and supraventricular arrhythmias. Dosing is weight-based and typically higher on a mg/kg basis than in adults due to a larger volume of distribution and more rapid renal clearance. Close monitoring of serum levels is essential. Neonates and infants may be more sensitive to toxic effects.

Geriatric Considerations

Elderly patients are at significantly increased risk of digoxin toxicity due to age-related decline in renal function (even with a “normal” serum creatinine), reduced lean body mass (leading to a lower volume of distribution), and increased sensitivity to drug effects. Lower doses and target serum concentrations (0.5-0.8 ng/mL) are recommended. Polypharmacy also increases the risk of dangerous interactions.

Renal and Hepatic Impairment

Renal Impairment: This is the most critical pharmacokinetic consideration for digoxin and milrinone. For digoxin, dosing must be reduced and dosing interval potentially lengthened based on estimated creatinine clearance (e.g., using the Cockcroft-Gault formula). Serum level monitoring is mandatory. For milrinone, dose reduction and extended monitoring are required as its half-life becomes markedly prolonged.

Hepatic Impairment: Digoxin is not significantly metabolized, so hepatic disease has minimal impact on its pharmacokinetics. Dobutamine and milrinone may have altered metabolism or clearance in severe liver disease, but clinical data are limited; careful titration to effect is necessary.

Summary/Key Points

• Cardiac glycosides (e.g., digoxin) exert positive inotropy primarily by inhibiting Na⁺/K⁺-ATPase, leading to increased intracellular calcium availability for contraction. They also have significant vagomimetic effects on the SA and AV nodes.
• Intravenous inotropes like dobutamine (β₁-agonist) and milrinone (PDE-III inhibitor) work by increasing intracellular cAMP, but have different hemodynamic profiles: dobutamine can increase heart rate and contractility, while milrinone provides inotropy with concomitant vasodilation.
• The therapeutic use of digoxin is now limited to adjunctive therapy for symptomatic chronic HFrEF and for rate control in atrial fibrillation, particularly in patients with concomitant heart failure. It does not improve mortality.
• Intravenous inotropes are reserved for acute, inpatient management of decompensated heart failure with hypoperfusion, typically as a bridge to definitive therapy or for palliative support.
• Digoxin has a very narrow therapeutic index. Toxicity is common and can be life-threatening, presenting with gastrointestinal, neurological, and a wide variety of cardiac arrhythmias. Hypokalemia, renal impairment, and drug interactions (especially with P-gp inhibitors like amiodarone and verapamil) are major risk factors.
• Renal function is the primary determinant of digoxin and milrinone clearance. Dosing must be meticulously adjusted in renal impairment. Elderly patients are at particularly high risk for toxicity.
• Digoxin-specific antibody fragments are the antidote for severe, life-threatening digoxin toxicity.

Clinical Pearls

• Therapeutic serum digoxin levels for heart failure are lower (0.5-0.9 ng/mL) than historically targeted. Levels ≥1.2 ng/mL are associated with increased toxicity and mortality.
• In atrial fibrillation, digoxin controls resting heart rate well but is ineffective for controlling rate during activity; combination with a beta-blocker is often optimal.
• Always check potassium, magnesium, and renal function before initiating digoxin and during therapy, especially if the patient is on diuretics.
• When starting a drug known to interact with digoxin (e.g., amiodarone), empirically reduce the digoxin dose by 30-50% and re-check serum levels within one week.
• In acute heart failure, the choice between dobutamine and milrinone hinges on the patient’s blood pressure and systemic vascular resistance: milrinone is more likely to cause hypotension but is useful when afterload reduction is desired.
• Visual disturbances (e.g., yellow vision) and new gastrointestinal symptoms in a patient on digoxin should prompt immediate evaluation for toxicity, including an ECG and serum digoxin level.

References

1. Opie LH, Gersh BJ. Drugs for the Heart. 9th ed. Philadelphia: Elsevier; 2021.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
4. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
7. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.